Genmab shares rose 6.84% over the week, but the supplied information doesn’t identify a company-specific reason for the gain.
The available headlines cover AbbVie and broader cancer-drug spending. Neither reports a Genmab announcement or explains the share-price move.
Investor takeaway: The weekly gain is clear, but its cause and any related catalyst remain unconfirmed.
Advertisement
Genmab AS
GMAB.US
GMAB.US
Genmab AS
WealthAwesomeMarket cap
$24.02B
P/E
30.8x
52W high
$40.17
52W low
$23.62
1W change
+6.84%
Beta
0.65
Analyst Price Targets
Based on 12 analysts covering GMAB · as of Oct 21, 2026
Wall Street analysts forecast GMAB stock price to rise 15.3% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
C$45.04
+15.3% Upside
Previously C$44.40 on Oct 14, 2026
Current Price
C$39.07
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GMAB's historical volatility
30-Day Vol
41.9%
Annualized
90-Day Vol
33.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$46.71
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$41.47 | C$35.88 – C$47.92 |
| 60 trading days | C$44.01 | C$35.87 – C$53.99 |
| 90 trading days | C$46.71 | C$36.36 – C$60.00 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Genmab gained 6.84% over one week
Genmab’s latest close was US$39.37, within its 52-week range of US$23.62 to US$40.17. Latest volume was 116,512 shares, compared with a 20-day average of 4,273,789.
Bull case
Genmab shares gained 6.84% over the week and closed at US$39.37, near the top of the supplied 52-week range.
Bear case
The supplied information doesn’t identify a company-specific reason for the gain. Latest volume was also below the 20-day average.
What happened: Genmab rose 6.84% over the week
The reported move is a 6.84% gain over one week. The supplied facts don’t include a dated company announcement, clinical update, earnings release, or other Genmab event that explains it. The two news headlines cover AbbVie’s oncology plans and projected cancer-drug spending, but neither points to a Genmab-specific catalyst. The share-price gain is clear; its cause isn’t established by the available information. Visit Genmab’s stock page at GMAB.US.
Advertisement
What the numbers show: US$39.37 close, with light volume
Genmab’s latest close was US$39.37. The shares gained 1.48% in one day, 12.46% in one month, and 22.78% year to date, alongside the reported 6.84% weekly gain. Latest volume was 116,512 shares, or 0.88 times the supplied 20-day average of 4,273,789. The 52-week range was US$23.62 to US$40.17, putting the close at 95% of that range.
The supplied fundamentals include a P/E of 30.7638, a market capitalization of 24,024,242,176, a profit margin of 19.1%, and trailing-twelve-month EPS of 1.27.
What to watch next: a company-specific explanation
The supplied facts don’t identify an upcoming Genmab event or confirm what prompted the weekly gain. Investors should distinguish the observed share-price move from a verified company development. The headlines about AbbVie and cancer-drug spending don’t explain the gain. No next catalyst is specified in the available information. Visit Genmab’s stock page at GMAB.US.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
